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Introduction
Cancer is driven by somatic driver mutations such as single nucleotide variants (SNVs), insertions-deletions (indels) and copy number alterations (CNAs) that affect critical genes and pathways. Driver mutations unlock oncogenic cellular properties of unconstrained proliferation, replicative immortality, immune evasion and the other hallmarks of cancer 1 . Completing the catalogue of cancer driver mutations is a central challenge of cancer research and key to understanding tumor biology, developing precision therapies and molecular biomarkers.
The search for driver mutations is complicated by the high rate of somatic 'passenger' mutations that have no biological significance. Statistical methods are used to distinguish between drivers and passengers in cancer genome sequencing datasets. These methods assume that somatic driver mutations occur more frequently than expected from background mutation rates, have unexpectedly high functional impact and show enrichment in biological pathways and networks (reviewed in [2] [3] [4] ). Driver discovery is facilitated by large genomic datasets assembled by consortia like the International Cancer Genome Consortium (ICGC) 5 and The Cancer Genome Atlas (TCGA) 6 . The notable driver mutation in the TERT promoter that confers replicative immortality on cells by inhibiting telomere-related cellular senescence was first identified in melanoma 7, 8 and then in pan-cancer analyses 9, 10 .
These mutations create new transcription factor (TF) binding sites (TFBS) which increase TERT transcription 11 . Other genes with frequent promoter mutations include the protein-coding genes PLEKHS1, WDR74 and SDHD 9, 10 along with the long non-coding RNAs (lncRNAs) NEAT1 and MALAT1 12 . Genome-wide driver discovery studies are limited to gene-focused genomic regions such as promoters and untranslated regions (UTRs) rather than experimentally defined regulatory regions.
Alternative approaches have scanned the genome with fixed-width windows 10, 13 , defined windows around mutation hotspots 9, 14 , or annotated cancer mutations using cis-regulatory information 14, 15 . Window-based approaches do not capture the precise boundaries of regulatory elements while annotation-based approaches conduct limited statistical testing of mutations. Current approaches are also unable to determine potential target genes of distal mutations.
Driver discovery in the non-coding regulatory genome is challenged by complex overall distribution of somatic mutations. At the megabase scale, mutation burden is associated with transcriptional activity and replication timing 16, 17 . Open chromatin is generally characterized by fewer somatic mutations while enhancers of the tissue of origin accumulate more mutations 18, 19 . At the nucleotide scale, mutation signatures are manifested in uneven distribution of mutations in their trinucleotide context. Different signatures are characteristic of different tumor types and have been linked to aberrant activity of DNA repair pathways, effects of various carcinogens or molecular clocks 20 . Genome-wide analyses of short sequence motifs bound by TFs have revealed increased mutation rates in regulatory regions 21 , for example excessive promoter mutations melanoma and other cancer types are likely explained by decreased activity of the nucleotide excision repair pathway 22, 23 . These studies suggest that a large fraction of gene regulatory mutations are caused by local mutational processes rather than positive selection driving tumor evolution.
The eukaryotic genome is organized three-dimensionally in the nuclear space to enable its functions, including transcription regulation via long-range interactions of promoters and enhancers and TF binding 24 . Binding sites of the CTCF chromatin architectural factor and the cohesin complex subunit RAD21 co-occur at topologically associated domain boundaries engaged in long-range chromatin interactions 24, 25 and are frequently mutated in colorectal cancer 26 . Anchors of chromatin interactions include functional genetic polymorphisms 27, 28 and are enriched in mutations in liver and esophageal cancers 29 . The MYC super-enhancer locus at 8q24 harbors SNVs with genetic predisposition for multiple tumor types 30, 31 and its deletion in mice was recently associated with reduced tumorigenesis 32 .
Recurrent somatic mutations in enhancers of PAX5 and TAL1 have been found in leukemia and associated with differential gene expression 33, 34 . Structural rearrangements in medulloblastoma and leukemia cause enhancer hijacking where oncogene expression is induced through translocations that associate oncogenes with active enhancers 35, 36 . Thus some mutations at gene regulatory sites may drive cancer by re-configuring gene regulatory interactions or the three-dimensional folding of chromatin. Surprisingly, then, a systematic driver analysis of non-coding mutations in cis-regulatory and three-dimensional chromatin interaction networks is currently lacking.
To fill this gap and to explore the effects of non-coding somatic mutations on gene-regulatory networks, we used 2,583 tumor-normal pairs characterized with whole genome sequencing (WGS) by the ICGC-TCGA Pan-cancer Analysis of Whole Genomes (PCAWG) project. We identified candidate drivers in regulatory regions of the human genome defined by the Encyclopedia of DNA Elements (ENCODE) 37 , then integrated these with the three-dimensional architecture of the human genome to prioritize and interpret candidate non-coding cancer drivers and their potential target genes. We found dozens of frequently mutated regulatory elements (FMREs) that were enriched in somatic small mutations and structural variants and overrepresented in active regulatory elements. Mutations in FMREs associated with altered expression of target genes, suggesting that our findings include novel driver mutations that rewire gene regulatory networks.
Results

Genome-wide discovery of cancer driver mutations with ActiveDriverWGS
We used the ICGC-PCAWG dataset of 2,583 whole cancer genomes for driver discovery and focused on mutations from 1,844 genomes from 31 cancer types, comprising 14.2 million single nucleotide variants and indels [PCAWG marker paper] (Supplementary Figure 1) . We excluded four cancer types with atypical mutational processes: melanomas with elevated mutation rates in active TFBS 22 , lymphomas with localized hypermutations 38 , and liver and esophageal cancers with frequent mutations in topologically associated CTCF binding sites 29 (Supplementary Note, Supplementary Figure 2) . We also excluded a small subset of hypermutated tumors (69) that carried 47% of all somatic mutations.
To find non-coding cancer drivers in whole cancer genomes, we created ActiveDriverWGS, a genome-wide driver discovery method that statistically identifies genomic regions with an elevated frequency of somatic mutations ( Figure   1a ). ActiveDriverWGS performs a statistical analysis of single nucleotide variants (SNVs) and small insertions-deletions (indels) relative to adjacent background sequences using Poisson generalized linear regression, expanding our earlier work on protein-coding drivers 39 . The model estimates expected mutation burden through a relatively narrow adjacent window and is therefore less sensitive to mega-base scale fluctuation of mutation rates. To adjust for nucleotide-level mutational signatures that vary considerably across patients and tumor types 20 , the model includes covariates for the frequency of each mutation type in its trinucleotide context. ActiveDriverWGS additionally predicts mutation impact by detecting frequently mutated binding sites within candidate driver genes and noncoding regions.
We validated ActiveDriverWGS by confirming its ability to recover known protein-coding and non-coding cancer drivers in the pan-cancer cohort and individual cancer types. We detected 47 coding genes (FDR<0.05) in a pan-cancer analysis, including 43 known drivers annotated in the Cancer Gene Census database 40 (Fisher's exact P=3.0x10 -62 , Figure 1b) . Driver analyses of 31 cancer type specific cohorts revealed 70 genes and 59 known drivers in total (Supplementary Figure 3) . Among non-coding consensus regions studied in PCAWG , we recovered previously described non-coding regions with frequent mutations such as promoters of TERT and WDR74, the lncRNAs NEAT1 and MALAT1 as well as other candidates (Supplementary Figure 4) .
We benchmarked ActiveDriverWGS and found that our statistical framework is well-calibrated. We tested three independently generated sets of simulated somatic mutations including two from the PCAWG project and one internally generated set (Supplementary Figure 5) . We also tested three configuration changes in the driver discovery pipeline: genomic window sizes for determining background mutations, inclusion of hyper-mutated samples, and exclusion of model cofactors corresponding to trinucleotide sequence composition. ActiveDriverWGS was robust to the size of the background window, and our simulations showed that statistical strength was maximized with a 50 kbp window size. We further confirmed the importance of using trinucleotides for driver discovery, as exclusion of this cofactor greatly increased false positive findings among protein-coding drivers (47 vs 4 non-cancer genes found). As anticipated, inclusion of hypermutated samples in the pan-cancer analysis led to recovery of fewer known proteincoding drivers (26 vs 43 known driver genes found) likely due to their introduction of increased noise of passenger mutations (Supplementary Figure 5) . These data collectively show that ActiveDriverWGS accurately recovers known cancer driver genes and non-coding genome regions with frequent somatic mutations.
Driver analysis reveals frequently mutated regulatory elements (FMREs)
Having validated ActiveDriverWGS, we next sought to discover non-coding cancer drivers in cis-regulatory regions. We studied 4.5 million TFBS mapped in ENCODE 37 in chromatin immunoprecipitation with DNA sequencing (ChIP-seq) experiments.
We focused on 149,222 cis-regulatory modules (CRMs) that covered 103 Mbp and 3.3% of the genome. CRMs were defined by overlapping binding sites of at least two TFs that were observed in least two cell lines. To avoid confounding functional impact, CRMs segments overlapping coding regions and splice sites were excluded.
The majority of CRMs (75%) overlapped with no UTR or promoter of protein-coding gene, enhancer or lncRNA sequence studied in PCAWG (Supplementary Figure 6) . These experimentally defined CRMs represent lessexplored genomic space for driver discovery and are complementary to commonly Power analysis suggests that FMREs with relatively rare mutations are only discoverable in large patient cohorts (Supplementary Figure 9) . The PCAWG pancancer dataset is suitable for detecting effects three-folder smaller than for the largest PCAWG tumour-type specific cohorts (i.e. breast, prostate and pancreatic).
We show that FMREs exist, but have been below the detectable effect-size in the larger individual tumor-type studies published to date. Thus we need to use pancancer analyses and sequence larger cancer-specific cohorts in the future. To study mutational processes active in FMREs, we evaluated the mutation signatures of SNVs using sample-specific exposure predictions developed by PCAWG (Figure 2c ). As controls, we sampled genome-wide mutations from the samples that carried FMRE mutations. We found that FMRE mutations were between the 90 th and the 100 th percentile of germline variation of protein-coding drivers, similarly to known cancer genes (e.g. FOXA1, GATA3) and genes with cancer predisposition variants (e.g. CDKN1B). We also compared FMREs to common fragile sites 44 and flagged five regions as potentially problematic, including two with excess germline variation in PCAWG. Thus driver discovery of non-coding regions such as CRMs is challenged by germline variation with biological and technical cofactors.
However some regions may also undergo positive selection in somatic genomes and include cancer predisposition variants in the germline genomes of cancer patients.
FMREs are enriched in long-range chromatin interactions and superenhancers
To explore the potential role of FMREs as distal regulatory elements interacting with promoters of target genes, we studied chromatin long-range interactions representing the three-dimensional architecture of the genome. We annotated FMREs using loop anchors of 11,282 high-confidence chromatin interactions conserved in at least two cell lines derived from a public HiC dataset 24 . We found that 13/38 FMREs associated with distal genomic regions through 29 long-range chromatin interactions (Figure 3a ). This is a two-fold enrichment relative to occupancy-matched CRMs (PCRM=0.0028, 13 interactions expected) and five-fold genome-wide enrichment (PGW=3.0x10 -6 , 6 interactions expected), suggesting that the mutated FMREs are particularly frequently interacting with distal genomic regions.
To explore the potential role of FMREs as cis-regulatory elements, we used a dataset of 58,283 super-enhancers 45 
Chromatin interactions of FMREs reveal mutation impact on gene expression
To study the impact of candidate driver mutations in FMREs, we associated FMREs and putative target genes using high-confidence chromatin interactions. The resulting chromatin interaction network included 18/38 FMREs and 37 putative target genes that either shared promoter or 5'UTR sequence with FMREs (15 genes) or were distally associated to FMREs via long-range chromosomal interactions (22 genes) (Figure 3c) . The remaining 20 FMREs with no apparent target genes were excluded.
We tested associations of 11 FMREs and 22 potential target genes for differential gene expression and revealed seven (32%) genes (RCC1, CCNB1IP1, GSTA4, ICK, HIST1H2AI, ANG, ZKSCAN3) with differential mRNA abundance in samples with mutations in four FMREs (Chi-square P<0.05, FDR<0.14). We used the PCAWG transcription dataset 49, 50 . CCNB1IP1 (cyclin B1 interacting protein 1) encodes a ubiquitin E3 ligase that negatively regulates cell motility and invasion by inhibiting cyclin B1 51, 52 . The angiogenesis-related gene ANG interacting with the FMRE via chromatin loops also showed lower expression in FMRE-mutated samples (P=0.042).
The genes GSTA4 and ICK showed reduced expression in 6 breast and 3 bladder cancer samples with mutations in the FMRE 6:52860289 (P=0.027 and P=0.030 respectively) (Figure 4b) . The FMRE has mutations in 33 samples (7 expected by chance; FDR=5.8x10 -9 ), overlaps with the promoter of GSTA4, the small nuclear RNA RN7SK, and has long-range chromatin interactions with the promoter of ICK. GSTA4 encodes the metabolic enzyme glutathione S-transferase alpha 4 involved in cellular defense against toxic, carcinogenic, and pharmacologic compounds and stress-induced TP53 signaling for apoptosis 53 . ICK encodes the intestinal cell kinase involved in cell cycle 54 and implicated in proliferation and ciliogenesis in glioblastoma 55 . The FMRE is annotated as a super-enhancer in brain hippocampus and carries binding sites of 103 TFs. We first found this FMRE due to a mutation that associated with decreased H3K27ac level in prostate tumors (Figure   3b ). Reduced expression of GSTA4 and ICK and decreased level of the enhancerassociated histone mark in mutated samples fit the hypothesis that mutations at this 56 and a positive regulator of the cyclin D2 oncogene in multiple myeloma 57 . It has also been implicated in the promotion, migration and metastasis of colorectal 58, 59 , prostate 60 , and bladder cancer 61 . The adjacent histone gene HIST1H2AI interacting with the FMRE via chromatin loops also showed differential expression relative to mutations in this FMRE (P=0.038). 
Discussion
Only few non-coding cancer drivers are known to date. Their discovery requires large WGS datasets and detailed annotations of the regulatory genome. Thus the search space of driver discovery efforts has been limited to gene-focused regions of the genome. Here we performed a driver analysis of the cis-regulatory genome using the largest cancer WGS dataset available to date from the PCAWG project. We revealed the currently largest set of pan-cancer driver candidates, frequently 
Methods
Somatic mutations
We analyzed the dataset of 1,844 whole cancer genomes of 31 cancer types with 14.2 million somatic single nucleotide variants (SNVs) and indels . This 
Genomic regions
Our driver discovery pipeline was run separately for multiple classes of genomic regions of the human genome hg19. Cis-regulatory modules from the ENCODE project comprised clusters of transcription factor (TF) binding sites (TFBS) measured in chromatin immunoprecipitation (ChIP-seq) experiments retrieved from UCSC Genome Browser. We used the dataset of 4.9 million binding sites of 161
TFs in 91 cell lines and excluded sites that were only observed in one cell line. The remaining 1.1 million binding sites of 101 TFs were merged into consecutive regions based on ≥1bp of common sequence, resulting in 322,614 regions. We discarded regions bound by single TFs and used the remaining 149,222 clusters of TFBS (i.e., cis-regulatory modules, CRMs) for driver discovery. CRMs were filtered to exclude sequence regions overlapping with coding sequence and splice sites. In addition to CRMs, we performed driver discovery on protein-coding sequences (CDS), untranslated regions of protein-coding genes (5'UTR, 3'UTR), promoters of coding genes (promDomain), and gene bodies of long non-coding RNAs (lncRNA) derived from the PCAWG consensus dataset .
ActiveDriverWGS and driver discovery
Candidate cancer driver genes and regulatory regions were identified with ActiveDriverWGS, our novel mutation enrichment method that tests whether a genomic element of interest is significantly more mutated than the relevant background sequence using a generalized linear regression model. ActiveDriverWGS Power calculations for chi-squared tests in ActiveDriverWGS were conducted using the pwr.chisq.test function of the 'pwr' package in R. Effect size was computed using number of samples, final degrees of freedom from ActiveDriverWGS output (1), and significance level (P=0.05). This process was repeated for several values of power (0.6-0.9) and data were plotted as line plots.
The R source code of ActiveDriverWGS is freely available at https://github.com/reimandlab/ActiveDriverWGS.
Benchmarking of ActiveDriverWGS
We tested ActiveDriverWGS using simulated mutations and parameter settings. To generate simulated mutation data, we split the genome into 50kb windows and randomly re-assigned PCAWG pan-cancer single nucleotide variants in each window to alternative positions of the same trinucleotide context using sampling with replacement. Indels were randomly re-assigned without using trinucleotide context.
Besides in-house simulated data, we also tested ActiveDriverWGS on two additional sets of simulations from the PCAWG drivers group (Sanger, Broad). In total 672 simulation runs with three sets of simulated mutations, 32 cancer types and seven types of genomic elements revealed eleven significant findings at FDR<0.05, suggesting that very little deviation existed from expected false discovery rates. We also tested ActiveDriverWGS with different sizes of background windows: ±10kb, ±25kb, ±50kb, ±75kb, and ±100kb. We found that the method is robust to variations in background window, however the ±50kb window provided the best accuracy and enrichment of known cancer genes. We also excluded the trinucleotide cofactor in our regression models and observed a large increase in false positive findings. We repeated the analysis after including hyper-mutated samples and found that many fewer known driver genes were detected. Thus hyper-mutated samples were excluded from the analysis.
Additional driver discovery methods
Four independent driver discovery methods were used to discover candidate drivers among CRMs. Each method used different statistical models, cofactors, mutation impact scores and/or clustering metrics to find candidate drivers. NBR uses a negative binomial regression to estimate the background mutation rate of each element as described earlier 41 . This method accounts for the length of each element and its mutability using a trinucleotide substitution model with 192 rate parameters and uses the local mutation rate in regions around each element as a covariate. DriverPower DriverPower is a combined burden and functional impact test for coding and non-coding cancer driver elements. In the DriverPower framework, randomized non-coding genome elements are used as training set. In total 1373 reference features covering nucleotide compositions, conservation, replication timing, expression levels, epigenomic marks and compartments are collected from public databases for downstream modelling. For the modelling, a feature selection step by randomized Lasso is performed at first. Then the expected background mutation rate is estimated with selected highly important features by binomial generalized linear model. The predicted mutation rate is further calibrated with functional impact scores measured by LINSIGHT 69 scores. Finally, a p-value is generated for each test element by binomial test with the alternative hypothesis that the observed mutation rate is higher than the adjusted mutation rate, and the Benjamini-Hochberg procedure is used for FDR control. OncoDriveFML, Driver discovery with OncoDriveFML was performed as described in the PCAWG driver study . MutSigCV. Driver discovery with MutSigCV was performed as described in the PCAWG driver study .
Super-enhancers and long-range chromatin interactions
We annotated FMREs using public datasets of long-range chromatin interactions and super-enhancers. The super-enhancer dataset originates from the study by Hnisz et al 45 . Chromatin loops representing long-range interactions from eight human cell lines were derived from the HiC dataset by Rao et al 24 . To obtain a highconfidence set of chromatin interactions, we merged interactions whose loop anchors overlapped with each other at both ends, and filtered those interactions that had been characterized only in one cell line. Long-range chromatin interactions were considered to interact with a gene if one anchor of the loop overlapped the coding, UTR or promoter sequence of the gene while the other anchor of the loop had no overlap with the gene. We also tested the aggregated set of H3K27ac and DNAse sites from the Roadmap Epigenomics project 70 . To determine statistical significance of genomic annotations of FMREs, we tested the union of all sequences corresponding to anchors using the two permutation strategies described below.
Enrichment of regulatory annotations of FMREs
We counted the number of pairs of FMREs and distinct genomic annotations. To determine the statistical significance of enriched genomic annotations of FMREs, we used a custom permutation test to sample from all CRMs from ENCODE as controls.
We split our initial dataset of ~150,000 CRMs into 100 equal bins based on their TF occupancy, represented as number of TFs bound in CRM divided by length of region.
To estimate the expected number of regulatory annotations in FMREs, we sampled 10,000,000 random sets of CRMs from the bins using the number and size distribution of detected FMREs. Statistical significance of enriched annotations was estimated as an empirical p-value, i.e., the fraction of 10,000,000 permutations that showed equivalent or higher number of regulatory annotations than associated with the true set of FMREs. To avoid biasing our findings by known non-coding drivers, we excluded three FMREs overlapping with the TERT promoter, the WDR74 promoter and the lncRNA MALAT1. Besides length-adjusted sampling of CRMs, we also sampled random genome regions of equivalent sizes as controls. Confidence intervals for observed numbers of FMRE annotations were derived with resampling.
Copy number alterations and structural variants
Matching copy number and structural variation datasets originate from the PCAWG project . We determined relative digital copy numbers of all regions and patients by accounting for previously computed sample ploidy estimates, whole genome duplication events, and patient sex. To estimate the frequency and enrichment of copy number alteration events in FMREs, we focused on focal and potentially high-impact copy number alterations with less than 5 mbp in size and total copy number of zero (corresponding to homozygous deletion) or relative gain of two or more copies. For structural variants, we studied coordinates of breakpoints. To determine statistical significance, we used permutation tests relative to all occupancy-matched ENCODE CRMs as well as size-matched random regions from the genome, using the strategy defined above. For analysis of mutation impact on gene expression, copy number altered regions were further processed to obtain gene-level copy number estimates. Copy numbers of genes were computed as the most extreme copy number values of their exons.
Mutation signature analysis
To analyse mutation signatures characteristic of FMREs, we studied sample-specific exposure predictions for SNVs developed by PCAWG . As controls, we sampled two sets of mutations in the cancer samples with FMRE mutations: SNVs present in 59 protein-coding drivers predicted by ActiveDriverWGS, and genomewide SNVs. We conducted custom permutation tests with 100,000 sets of SNVs that were sampled with replacement using the number of mutations observed in FMREs and their distribution among cancer types. We computed the enrichment of each 
Germline analysis
Germline variant frequency of FMREs was estimated using density of unique SNVs and indels in 100 bp windows across the entire PCAWG cohort of cancer patients. As reference we used the protein-coding drivers identified by ActiveDriverWGS in the pan-cancer cohort. We computed germline variant density within genomic elements and estimated the upper bound of expected variation for within-element variation as 90 th and 100 th percentiles of values observed among coding driver predictions.
FMREs that exceeded the 100 th percentile threshold were flagged for excess germline variation. We also computed germline variation density for frequently mutated promoters, UTRs, enhancers and lncRNAs discovered by ActiveDriverWGS in the pan-cancer driver analysis.
Mutation impact on gene expression
We used matching RNAseq gene expression data from PCAWG were included and others were excluded. Cancer types with fewer mutated samples were also removed from the control (non-mutated) set. Each FMRE was tested using pan-cancer mutations with cancer type as a nominal co-factor and relative copy number as a numeric cofactor. Two sets of genes were tested for every FMRE: genes or their promoters directly overlapping with an FMRE, and genes distally associated with an FMRE via a long-range chromatin interaction of gene promoter. Genes with P<0.05 were selected as significant and FDR values were computed across all tested pairs and reported (FDR<0.15).
Global gene expression and pathway enrichment analysis
Global analysis of gene expression in samples with mutations in the FMRE upstream of RCC1 was conducted with the same statistical approach as for single target genes.
We tested protein-coding genes that had at least one GO annotation and showed 
Mutation vetting
Mini-BAM files for samples with a variant in the following FMREs were downloaded from GNOS: chr1:28831933-28842995, chr6:52859342-52861236, chr6:27869931-27871319 and chr14:21081147-21082486. FMRE variants were manually examined in the IGV software v2.3.97. Variants that were missing or were called within palindromic regions were marked as false positives. Variants were flagged as low confidence if they occurred on one strand (forward or reverse), had fewer than four reads, or were found within a homopolymer run. Variants were highlighted, but not flagged, if they had four supporting reads, only one supporting read on one of the strands, in a low coverage region, or in a region with strand bias. Variants found in regions with strand bias, and showed strand bias in their supporting reads were highlighted, but not flagged.
ChIP-seq data of primary prostate cancers
We used a recent ChiP-seq dataset for the histone mark H3K27ac in 19 PCAWG prostate cancer samples 48 . We examined the dataset to find overlaps of FMREs and H3K27ac peaks. Global overlap of FMREs and H3K27ac peaks was determined using the permutation strategy and the two types of control regions described above. To evaluate mutation impact on specific H3K27ac peaks within FMREs, the FMREs were extended by 1Kb up and downstream, and rounded to the nearest 100 bp before intersecting with H3K27ac regions determined in ChiP-seq files. Patients with an H3K27ac peak in the target region were considered to have an enhancer mark in proximity to the FMRE. Peak scores were subsequently converted to zscores and plotted as boxplots.
